Literature DB >> 4140328

Prednisone in Duchenne muscular dystrophy.

D B Drachman, K V Toyka, E Myer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4140328     DOI： 10.1016/s0140-6736(74)90071-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  37 in total

1.  Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.

Authors:  Luca Bello; Heather Gordish-Dressman; Lauren P Morgenroth; Erik K Henricson; Tina Duong; Eric P Hoffman; Avital Cnaan; Craig M McDonald
Journal:  Neurology       Date:  2015-08-26       Impact factor: 9.910

2.  The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies.

Authors:  Mahmoud R Hussein; Sherifa A Hamed; Mohammed G Mostafa; Eman E Abu-Dief; Nageh Fouly Kamel; Mahmoud R Kandil
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

Review 3.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

4.  Effects of dexamethasone in myotonic muscular dystrophy.

Authors:  J Streifler; C Gordon; N Gadoth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-07       Impact factor: 10.154

Review 5.  Biochemical events associated with rapid cellular damage during the oxygen- and calcium-paradoxes of the mammalian heart.

Authors:  C J Duncan
Journal:  Experientia       Date:  1990-01-15

6.  Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne muscular dystrophy during glucocorticoid treatment.

Authors:  H Kawai; K Adachi; Y Nishida; T Inui; C Kimura; S Saito
Journal:  J Neurol       Date:  1993       Impact factor: 4.849

7.  Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy.

Authors:  Kitipong Uaesoontrachoon; James L Quinn; Kathleen S Tatem; Jack H Van Der Meulen; Qing Yu; Aditi Phadke; Brittany K Miller; Heather Gordish-Dressman; Ennio Ongini; Daniela Miglietta; Kanneboyina Nagaraju
Journal:  Hum Mol Genet       Date:  2014-01-23       Impact factor: 6.150

8.  Sporadic distal myopathy.

Authors:  M L Vaccario; C Scoppetta; R Bracaglia; A Uncini
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

9.  Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic program.

Authors:  Alexander Morrison-Nozik; Priti Anand; Han Zhu; Qiming Duan; Mohamad Sabeh; Domenick A Prosdocimo; Madeleine E Lemieux; Nikolai Nordsborg; Aaron P Russell; Calum A MacRae; Anthony N Gerber; Mukesh K Jain; Saptarsi M Haldar
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-23       Impact factor: 11.205

Review 10.  Therapeutics for Duchenne muscular dystrophy: current approaches and future directions.

Authors:  Sasha Bogdanovich; Kelly J Perkins; Thomas O B Krag; Tejvir S Khurana
Journal:  J Mol Med (Berl)       Date:  2003-12-12       Impact factor: 4.599
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.